Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-24T18:04:51.941Z Has data issue: false hasContentIssue false

Chapter 14 - Ataxia

Published online by Cambridge University Press:  05 July 2015

By
Marina Sanchez Abraham  and
Oscar S. Gershanik
Edited by
Joseph H. Friedman
Joseph H. Friedman
Affiliation:
Department of Neurology, Brown University
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Medication-Induced Movement Disorders , pp. 150 - 159
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Factor, S, Lang, A, Weiner, W (Eds). Drug induced movement disorders. Wiley-Blackwell; 2nd edition, 2005.CrossRefGoogle Scholar
Manto, M. Toxic agents causing cerebellar ataxias. Handb Clin Neurol. 2012;103:201–13.CrossRefGoogle ScholarPubMed
Naranjo, CA, Busto, U, Sellers, EM, Sandor, P, Ruiz, I, et al. A method for estimating the probability of adverse drug reactions. Clin Pharacol Ther. 1981; 30:239–45.Google ScholarPubMed
Gilman, S, Bloedel, JR, Lechtenberg, R. Disorders of the cerebellum. Philadelphia: FA Davis Co (Ed), 1981.Google Scholar
Mariotti, C, Fancellu, R, Di Donato, S. An overview of the patient with ataxia. J Neurol. 2005; 252(5):511–8.CrossRefGoogle ScholarPubMed
Curtis, DL, Piibe, R, Ellenhorn, MJ, Wasserberger, J, Ordog, G. Phenytoin toxicity: a review of 94 cases. Vet Hum Toxicol. 1989; 31(2):164–5.Google ScholarPubMed
Ghatak, NR, Santoso, RA, McKinney, WM. Cerebellar degeneration following long term phenytoin therapy. Neurology. 1976; 26:818–820.CrossRefGoogle ScholarPubMed
McLain, LW Jr, Martin, JT, Allen, JH. Cerebellar degeneration due to chronic phenytoin therapy. Ann Neurol. 1980; 7:18–23.CrossRefGoogle ScholarPubMed
Baier, WK, Beck, U, Doose, H, Klinge, H, Hirsch, W. Cerebellar atrophy following diphenylhydantoin intoxication. Neuropediatrics. 1984;15(2):76–81.CrossRefGoogle ScholarPubMed
Ney, GC, Lantos, G, Barr, WB, Schaul, N. Cerebellar atrophy in patients with long-term phenytoin exposure and epilepsy. Arch Neurol. 1994; 51:767–71.CrossRefGoogle ScholarPubMed
Alioğlu, Z, Sari, A, Velioğlu, SK, Cerebellar atrophy following acute phenytoin intoxication. J Neuroradiol. 2000; 27(1):52–5.Google ScholarPubMed
Seymour, JF. Carbamazepine overdose. Features of 33 cases. Drug Saf. 1993; 8:81–88.CrossRefGoogle ScholarPubMed
Specht, U, May, TW, Rohde, M, et al. Cerebellar atrophy decreases the threshold of carbamazepine toxicity in patients with chronic focal epilepsy. Arch Neurol. 1997; 54:427–431.CrossRefGoogle ScholarPubMed
Zaccara, G, Giovannelli, F, Maratea, D, Fadda, V, Verrotti, A. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure. 2013; 22(7):528–36.CrossRefGoogle Scholar
Steinhoff, BJ, Herrendorf, G, Bittermann, HJ, Kurth, C. Isolated ataxia as an idiosyncratic side-effect under gabapentin. Seizure. 1997; 6(6):503–4.CrossRefGoogle ScholarPubMed
Sander, JW, Hart, YM, Trimble, MR, Shorvon, SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry. 1991; 54(5):435–9.CrossRefGoogle ScholarPubMed
Fife, TD, Blum, D, Fisher, RS. Measuring the effects of antiepileptic medications on balance in older people. Epilepsy Res. 2006; 70(2–3):103–9.CrossRefGoogle ScholarPubMed
Chayasirisobhon, S, Chayasirisobhon, WV, Tsay, CC. Acute levetiracetam overdose presented with mild adverse events. Acta Neurol Taiwan. 2010; 19(4):292–5.Google ScholarPubMed
Sirven, JI, Fife, TD, Wingerchuk, DM, Drazkowski, JF. Second-generation antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clin Proc. 2007; 82(1):40–7.CrossRefGoogle ScholarPubMed
Carmichael, K, Pulman, J, Lakhan, SE, Parikh, P, Marson, AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2013; 12.CrossRefGoogle Scholar
Brodie, MJ, Rosenfeld, WE, Vazquez, B, Sachdeo, R, Perdomo, C, Mann, A, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia. 2009; 50(8):1899–909.CrossRefGoogle ScholarPubMed
Ben-Menachem, E, Biton, V, Jatuzis, D, Abou-Khalil, B, Doty, P, Rudd, GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007; 48(7):1308–17.CrossRefGoogle ScholarPubMed
Riehl, J, Brown, WJ. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology. 1964; 14:961–7.CrossRefGoogle ScholarPubMed
Phillips, PC, Reinhard, CS. Antipyrimidene neurotoxicity: cytosine arabinoside and 5-fluorouracil. In: Rottenberg, DA, editor. Neurological complications of cancer treatment. Boston: Butterworth-Heinemann, 1991:97–114.Google Scholar
Herzig, RH, Hines, JD, Herzig, GP, et al. Cerebellar toxicity with high dose cytosine arabinoside. J Clin Oncol. 1987; 5:927–32.CrossRefGoogle ScholarPubMed
Hwang, TL, Yung, A, Estey, EH, et al. Central nervous system toxicity with high dose Ara-C. Neurology. 1985; 35:1475–7.CrossRefGoogle ScholarPubMed
Baker, WJ, Royer, GL Jr, Weiss, RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991; 9:679–93.CrossRefGoogle ScholarPubMed
Courtney, MJ, Coffey, ET. The mechanism of Ara-C-induced apoptosis of differentiating cerebellar granule neurons. Eur J Neurosci. 1999; 11(3):1073–84.CrossRefGoogle ScholarPubMed
Dworkin, LA, Goldman, RD, Zivin, LS, Fuchs, PC. Cerebellar toxicity following high-dose cytosine arabinoside. J Clin Oncol. 1985;3(5):613–6.CrossRefGoogle ScholarPubMed
Dietrich, J, Han, R, Yang, Y, Mayer-Proschel, M, Noble, M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006; 5(7):22.CrossRefGoogle ScholarPubMed
Sylvester, RK, Fisher, AJ, Lobell, M. Cytarabine-induced cerebellar syndrome: case report and literature review. Drug Intell Clin Pharm. 1987; 21(2):177–80.Google ScholarPubMed
Renouf, D, Gill, S. Capecitabine-induced cerebellar toxicity. Clin Colorectal Cancer. 2006; 6(1):70–1.CrossRefGoogle ScholarPubMed
Lam, MS, Kaufman, DA, Russin, MP. Capecitabine-associated cerebellar ataxia. Am J Health Syst Pharm. 2008; 65(21):2032–5.CrossRefGoogle ScholarPubMed
Gounaris, I, Ahmad, A. Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. J Oncol Pharm Pract. 2010; 16(4):277–9.CrossRefGoogle Scholar
Masterson, K, Merlini, L, Lovblad, KO. Coexistence of reversible cerebral neurotoxicity and irreversible cerebellar atrophy following an intrathecal methotrexate chemotherapy: two case reports. J Neuroradiol. 2008; 36(2):112–4.Google ScholarPubMed
Beer, TM, Higano, CS, Saleh, M, Dreicer, R, Hudes, G, Picus, J, Rarick, M, Fehrenbacher, L, Hannah, AL. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs. 2007; 25(6):565–70.CrossRefGoogle ScholarPubMed
Hindle, JV, Ibrahim, A, Ramaraj, R. Ataxia caused by amiodarone in older people. Age Ageing. 2008; 37:347–8.CrossRefGoogle ScholarPubMed
Charness, ME, Morady, F, Scheinman, MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology.1984; 34:669–71.CrossRefGoogle ScholarPubMed
Palakurthy, PR, Iyer, V, Meckler, RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern Med. 1987; 147:881–4.CrossRefGoogle ScholarPubMed
Krauser, DG, Segal, AZ, Kligfield, P. Severe ataxia caused by amiodarone. Am J Cardiol. 2005; 96:1463–4.CrossRefGoogle ScholarPubMed
Schwartz, AB, Klausner, SC, Yee, S, Turchyn, M. Cerebellar ataxia due to procainamide toxicity. Arch Intern Med. 1984; 144(11):2260–1.CrossRefGoogle ScholarPubMed
Odeh, M, Seligmann, H, Oliven, A. Propafenone-induced ataxia: report of three cases. Am J Med Sci. 2000; 320(2):151–3.CrossRefGoogle ScholarPubMed
Sarna, JR, Furtado, S, Brownell, AK. Neurologic complications of metronidazole. Can J Neurol Sci. 2013; 40(6):768–76.Google Scholar
Woodruff, BK, Wijdicks, EF, Marshall, WF. Reversible metronidazole-induced lesions of the cerebellar dentate nuclei. N Engl J Med. 2002; 346(1):68–9.CrossRefGoogle ScholarPubMed
Wolinsky, E, Hines, JD. Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. N Engl J Med. 1972; 266: 759–62.Google Scholar
Lewin, PK, McGreal, D. Isoniazid toxicity with cerebellar ataxia in a child. CMAJ. 1993; 148(1):49–50.Google ScholarPubMed
Manto, M, Godaux, E, Jacquy, J, Hildebrand, JG. Analysis of cerebellar dysmetria associated with lithium intoxication. Neurol Res. 1996; 18(5):416–24.CrossRefGoogle ScholarPubMed
Grignon, S, Bruguerolle, B. Cerebellar lithium toxicity: a review of recent literature and tentative pathophysiology. Therapie. 1996; 51(2):101–6.Google ScholarPubMed
Yamaguchi, I, Ichikawa, T, Nakao, K, Hamasaki, K, Hirano, K, Eguchi, S, Takatsuki, M, Kawasita, Y, Kanematsu, T, Eguchi, K. Cerebellar ataxia in a patient receiving calcineurin inhibitors after living donor liver transplantation: a case report. Transplant Proc. 2007; 39(10):3495–7.CrossRefGoogle Scholar
Kaleyias, J, Faerber, E, Kothare, SV. Tacrolimus induced subacute cerebellar ataxia. Eur J Paediatr Neurol. 2006; 10(2):86–9.CrossRefGoogle ScholarPubMed
Gordon, MF, Abrams, RI, Rubin, DB, Barr, WB, Correa, DD. Bismuth subsalicylate toxicity as a cause of prolonged encephalopathy with myoclonus. Mov Disord. 1995; 10(2):220–2.CrossRefGoogle ScholarPubMed
Masannat, Y, Nazer, E. Pepto bismuth associated neurotoxicity: A rare side effect of a commonly used medication. W V Med J. 2013; 109(3):32–4.Google ScholarPubMed
Playford, RJ, Matthews, CH, Campbell, MJ, Delves, HT, Hla, KK, Hodgson, HJ, Calam, J. Bismuth induced encephalopathy caused by tri potassium dicitrato bismuthate in a patient with chronic renal failure. Gut. 1990; 31(3):359–60.CrossRefGoogle Scholar
Teive, HA, Munhoz, RP, Werneck, LC. Acquired cerebellar ataxia due to statin use. Arq Neuropsiquiatr. 2012; 70(2):152.CrossRefGoogle ScholarPubMed
Musumeci, O, Naini, A, Slonim, AE, Skavin, N, Hadjigeorgiou, GL, Krawiecki, N, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology. 2001; 56:849–855.CrossRefGoogle ScholarPubMed
Awada, AA, Al-Mezem, S, Amene, PC. Phenytoin intoxication: burden and risk factors. Neurosciences (Riyadh). 2001; 6(3):166–8.Google ScholarPubMed
Pirzada, NA, Ali, II, Dafer, RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother. 2000; 34(1):35–8.CrossRefGoogle ScholarPubMed
Noguerón, E, Berrocal, A, Albert, A, Camps, C, Vicent, JM. [Acute cerebellar syndrome due to 5-fluorouracil]. Rev Neurol. 1997; 25(148):2053–4.Google ScholarPubMed
Barbieux, C, Patri, B, Cerf, I, de Parades, V. [Acute cerebellar syndrome after treatment with 5-fluorouracil]. Bull Cancer. 1996; 83(1):77–80.Google ScholarPubMed
Friedman, JH, Shetty, N. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman. Mov Disord. 2001 May; 16(3):575–7.CrossRefGoogle ScholarPubMed
Yeshurun, M, Marsot Dupuch, K. Acute cerebellar syndrome following intermediate-dose cytarabine. Br J Haematol. 2001; 113(4):846.CrossRefGoogle ScholarPubMed
Hasle, H. Cerebellar toxicity during cytarabine therapy associated with renal insufficiency. Cancer Chemother Pharmacol. 1990;27(1):76–8.CrossRefGoogle ScholarPubMed
Ferhanoglu, B, Ongören, S, Ar, CM, Uzel, B, Forta, H, Necioglu, D. Intrathecal methotrexate-induced acute cerebellar syndrome. Ann Hematol. 2003;82(4):241–3.CrossRefGoogle ScholarPubMed
Kobrinsky, B, Joseph, SO, Muggia, F, Liebes, L, Beric, A, Malankar, A, Ivy, P, Hochster, H. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity. Cancer Chemother Pharmacol. 2013; 72(5):1073–8.CrossRefGoogle ScholarPubMed
Chaubey, VK, Chhabra, L, Kapila, A. Ataxia: a diagnostic perplexity and management dilemma. BMJ Case Rep. 2013; 2013.CrossRefGoogle Scholar
Willis, MS, Lugo, AM. Amiodarone-induced neurotoxicity. Am J Health Syst Pharm. 2009; 66(6):567–9.CrossRefGoogle ScholarPubMed
Garretto, NS, Rey, RD, Kohler, G, Cocorullo, S, Monteverde, DA, Ravera, BI, Sica, RE. Cerebellar syndrome caused by amiodarone. Arq Neuropsiquiatr. 1994; 52(4):575–7.Google ScholarPubMed
Arnaud, A, Neau, JP, Rivasseau-Jonveaux, T, Marechaud, R, Gil, R. [Neurological toxicity of amiodarone. 5 case reports]. Rev Med Interne. 1992; 13(6):419–22.Google ScholarPubMed
Kuriyama, A, Jackson, JL, Doi, A, Kamiya, T. Metronidazole-induced central nervous system toxicity: a systematic review. Clin Neuropharmacol. 2011; 34(6):241–7.CrossRefGoogle ScholarPubMed
Niethammer, M, Ford, B. Permanent lithium-induced cerebellar toxicity: three cases and review of literature. Mov Disord. 2007; 22(4):570–3.CrossRefGoogle ScholarPubMed
Kaczmarek, I, Schmauss, D, Sodian, R, Beiras-Fernandez, A, Oberhoffer, M, Daebritz, S, Schoenberg, SO, Reichart, B. Late-onset tacrolimus-associated cerebellar atrophia in a heart transplant recipient. J Heart Lung Transplant. 2007; 26(1):89–92.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×